RAS Quantification in Patients With Aliskiren or Candesartan

Phase 4

Completed

• Conditions: Hypertension; Chronic Kidney Disease; Proteinuria
• Interventions: Other: RAS blockade discontinuation; Drug: Aliskiren; Drug: Candesartan

• Registration Number: NCT01827202
• Lead Sponsor: Medical University of Vienna

Brief Summary

Forced blockade of the renin-angiotensin-system (RAS) by using direct renin inhibition (DRI) has long been propagated to effectuate beneficial outcomes. However, recent large clinical trials have outlined harmful effects for DRI in combination with other forms of RAS blockade. To date, information regarding DRI as RAS-blocking monotherapy is very limited. Furthermore, it remains to be elucidated how DRI and angiotensin receptor blockers affect the so-called 'classical' and 'alternative' RAS molecularly. As components of the 'alternative' RAS (e.g. Ang 1-7) have moved into research focus, it would be of importance to determine angiotensin regulation with medical RAS blockade.

In this prospective, single-center randomized trial over 10 weeks, 24 patients with chronic kidney disease (CKD) stage III-IV (eGFR 15-59 ml/min) will be randomized to take either aliskiren (up to 300 mg per day) or candesartan (up to 16 mg per day) after a two week run-in phase where all RAS-blockers are eliminated. The investigators will then employ a novel mass spectrometry-based quantification method (after run-in and 10 weeks) to capture the concentrations of ten different angiotensin peptides (including angiotensin I and II, angiotensin 1-7 and angiotensin 1-5).

The investigators hypothesize that significant differences exist between angiotensin levels in CKD patients with DRI compared to angiotensin receptor blockers. Specifically, the investigators expect to determine the regulation of the alternative RAS represented by angiotensin 1-7 with proximal versus distal blockade of the system.

Our data might contribute to a more profound understanding of results from registries and clinical trials beyond the clinical effects of RAS blockade. Further, the study's results might help to individualize and optimize RAS-blocking therapy strategies in CKD patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-12
• Study First Submitted: 2013-04-04
• Study First Submitted QC: 2013-04-08
• Study First Posted: 2013-04-09
• Primary Completion: 2016-02
• Study Completion: 2016-02
• Status Verified: 2016-03
• Last Update Submitted: 2016-03-14
• Last Update Posted: 2016-03-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Chronic kidney disease stages III-IV (defined by modification of diet in renal disease (MDRD) formula)
• Urinary albumin to creatinine ratio (UACR) >300mg/g, UACR >200mg/g if already receiving RAS blockade
• Arterial hypertension

Exclusion Criteria

• Age <18 years
• Diabetes mellitus type 2 (defined by WHO criteria)
• Chronic kidney disease stage V (end-stage renal disease)
• UACR >3500mg/g
• Severe hypertension (systolic blood pressure >180mmHg)
• Pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Aliskiren	RAS blockade discontinuation	After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking aliskiren 150 mg once daily for 4 weeks. Thereafter, the dose will be increased to 300 mg once daily for another 4 weeks.
Aliskiren	Aliskiren	After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking aliskiren 150 mg once daily for 4 weeks. Thereafter, the dose will be increased to 300 mg once daily for another 4 weeks.
Candesartan	RAS blockade discontinuation	After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking candesartan 8 mg once daily for 4 weeks. Thereafter, the dose will be increased to 16 mg once daily for another 4 weeks.
Candesartan	Candesartan	After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking candesartan 8 mg once daily for 4 weeks. Thereafter, the dose will be increased to 16 mg once daily for another 4 weeks.

Primary Outcome Measures

Name	Time	Method
Mass spectrometry RAS peptide quantification	2 months	Quantitative RAS peptide changes determined by mass spectrometry after a 2-month treatment with aliskiren or candesartan

Secondary Outcome Measures

Name	Time	Method
Blood pressure	2 months	Blood pressure reduction, determined by ambulatory blood pressure measurements at study start and end
Proteinuria	2 months	Proteinuria reduction, measured by urinary albumin/creatinine ratio at study start and end

Trial Locations

Locations (1)

Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis; 🇦🇹 Vienna, Austria